TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05472259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Only administered in the investigational arm (Nalirinox): a dose of 60 mg/m² is administered in combination with nanoliposomal irinotecan, 5FU and Leucovorin
Study: NCT05137652

Intervention type: DEVICE
Group type: OTHER
Intervention: Radiofrequency ablation of medial nerve using single needle approach
Description: The primary outcome is to study the efficacy of the described technique which creates a lesion that we estimate to be 11.0-mm wide and 11.6-mm long along the course of the medial branch adjacent to the SAP ensuring adequate coverage and treatment using VAS score. Responder status was defined as a 30% or greater improvement in VAS pain score from the pre-procedural VAS pain score. Outcomes were summarized by means and standard deviations for continuous outcomes, and frequencies (%) for categorical outcomes.
Study: NCT04995536

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CpG-STAT3 siRNA CAS3/SS3
Description: Given intratumorally

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT05788055

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool Analysis
Description: Stool Analysis to detect H.Pylori Antigen in Stool

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool Analysis
Description: Stool Analysis to detect H.Pylori Antigen in Stool
Study: NCT05282069

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DA-8010 Placebo
Description: Participants receive placebo to match DA-8010 orally once a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DA-8010 Placebo
Description: Participants receive placebo to match DA-8010 orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-8010 2.5mg
Description: Participants receive DA-8010 2.5mg orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-8010 5mg
Description: Participants receive DA-8010 5mg orally once a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin 5mg
Description: Participants receive solifenacin 5 mg orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate placebo
Description: Participants receive placebo to match solifenacin 5 mg orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate placebo
Description: Participants receive placebo to match solifenacin 5 mg orally once a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Solifenacin succinate placebo
Description: Participants receive placebo to match solifenacin 5 mg orally once a day.
Study: NCT05983471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME-015 (Suplatast Tosilate)
Description: Oral capsule form, 200 mg t.i.d. (total 600 mg per 24 hours)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME-015 (Suplatast Tosilate)
Description: Oral capsule form, 200 mg t.i.d. (total 600 mg per 24 hours)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Identical placebo
Description: Without active component

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Identical placebo
Description: Without active component
Study: NCT05137652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation of medial nerve using three needle approach
Description: The primary outcome is to study the efficacy of the described technique by maximizing the lesion size (compared to control group) along the course of the medial branch adjacent to the SAP ensuring adequate coverage and treatment using VAS score.
Study: NCT05036993

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Faculty will be paired with a certified coach who is also a faculty member and receive 6 sessions of coaching over 3 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Faculty will be paired with a certified coach who is also a faculty member and receive 6 sessions of coaching over 3 months
Study: NCT05605262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Manukamed - Manukapli 100% sterile honey wound dressing - Premium medical grade 16+ Leptospermum Scoparium New Zealand honey
Description: After surgical reconstruction of the tympanic membrane by grafting, Manukamed - Manukapli 100% Sterile honey wound dressing is applied onto the gelfoam to close the area, followed by an antibiotic tampon.
Study: NCT06483971

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Oral Isotretinoin
Description: 20 mg/kg/day that affects sebaceous glands and is used to treat severe acne Frequency: Once daily

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: 250 mg on laternate day/3 months Frequency: Once or twice daily
Study: NCT05140577

Intervention type: OTHER
Intervention: Maximal voluntary isometric strengthening
Description: The subject is asked to perform a maximum voluntary isometric force work against a wall during 5 seconds

Intervention type: OTHER
Intervention: Maximal voluntary isometric strengthening
Description: The subject is asked to perform a maximum voluntary isometric force work against a wall during 5 seconds

Intervention type: OTHER
Intervention: Maximal voluntary isometric strengthening
Description: The subject is asked to perform a maximum voluntary isometric force work against a wall during 5 seconds
Study: NCT05570344

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: rTMS uses powerful (1.0-2.5 Tesla), focused magnetic field pulses to induce electrical currents in neural tissue noninvasively, via an inductor coil placed against the scalp.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS) Plus Text4Support
Description: rTMS uses powerful (1.0-2.5 Tesla), focused magnetic field pulses to induce electrical currents in neural tissue noninvasively, via an inductor coil placed against the scalp.~Text4Support:~Text4Support is one of the ResilienceNHope suites of supportive text messaging programs delivered by the Global Psychological eHealth Foundation \[80\]. The program allows users to receive daily supportive text messages which have been written by a team of cognitive-behavioral therapists and mental health professionals in collaboration with users of mental health services. The aim of this Text4Support depression program is to enhance positively the mood of patients with clinical depression. The program operates through the use of positive reinforcement to correct distorted or negative thought patterns.
Study: NCT06481956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib Oral Tablet
Description: Patients with advanced breast cancer with at least one evaluable lesion and histologically proven invasive breast cancer were eligible for inclusion. Histopathologically positive for HER2 (IHC 3+, or IHC 2+ with fluorescence in situ hybridization (FISH) positive, either primary or metastatic. Patients with advanced breast cancer must have previously received first-line therapy or initial rescue therapy and have been treated with trastuzumab against HER2.
Study: NCT05925036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: Autologous bone marrow derived MSCs

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Controls
Study: NCT05117307

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Injectable Solution
Description: Ultrasound-guided block with 20 ml %0.25 bupivacaine, per side

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Injectable Solution
Description: Ultrasound-guided block with 20 ml %0.25 bupivacaine, per side
Study: NCT06329765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise with CUped - a motor-assisted, split crank pedaling device and undergo 50 m of gait training.
Description: Exercise with CUped - a motor-assisted, split crank pedaling device and undergo 50 m of gait training.
Study: NCT06567054

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurements with the POROUS R3C ultrasound device at the midshaft tibia
Description: The POROUS R3C ultrasound device measures the cortical bone of the midshaft tibia. Ultrasound gel is first applied onto the skin surface, covering the region of interest, followed by placing the ultrasound transducer with a medical ultrasound gel pad placed in front of it. At the marked position on the leg, four technical measurement readings are performed: 2x CortBS and 2x Multifocus, with repositioning the probe between individual measurements, the chronological order of which is not crucial. Scanning time for each measurement takes 1-2 minutes. Out of the four measurements, the two optimal measurements (one for CortBS and one for Multifocus) are selected by the device, based on pre-defined quality criteria.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DXA measurement of the hip and lumbar spine
Description: The following DXA measurements are to be performed:~* Spine L1-4~* Hip left~* Hip right (alternatively, if a valid measurement of the left hip is not possible) Scanning takes approximately 15 minutes. A maximum number of one repeat measurement is planned (e.g., hip or spine). Note: The DXA scan of the hip is performed on the same side of the body as the POROUS R3C ultrasound scan.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DXA-based Vertebral Fracture Assessment (VFA)
Description: DXA-based Vertebral Fracture Assessment (VFA) of thoracic and lumbar spine from T4 to L5.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Projectional radiography of thoracic spine (alternative to DXA-based VFA, if VFA is not available)
Description: Projectional radiography of thoracic spine T4-T12 and lumbar spine L1-L5.
Study: NCT03409328

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV and substance use prevention
Description: The intervention content will be developed through formative research during the initial phase of the study. However, the intervention will address: bisexual-inclusive sexual health education, unique influences of risk behavior among bisexual adolescents, and skills to cope with bisexual stigma and to increase acceptance of one's bisexual identity.
Study: NCT05303844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H101
Description: H101 intratumorally injection starts at day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab will be initiated on day 1. Tislelizumab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
Study: NCT05156866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TORL-2-307-ADC
Description: antibody drug conjugate
Study: NCT05716061

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sacral ESPB
Description: Cadaver study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sacral ESPB
Description: Cadaver study
Study: NCT06317753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Participants allocated to the Aerobic condition will be following a 4 month-intervention aerobic exercise protocol of 3 weekly interleaved sessions with a 50 minutes duration

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Agility-Cognitive Exercise
Description: Participants allocated to the Agility-Cognitive condition will be following a 4 month-intervention agility-cognitive exercise protocol of 3 weekly interleaved sessions with a 50 minutes duration

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching/relaxation
Description: Participants allocated to the stretching control condition will be following a 4 month-intervention protocol of 1 weekly session with a 50 minutes duration
Study: NCT03984539

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy-Enhanced
Description: CBT-E is a 20-session transdiagnostic eating disorders treatment based on the principles of cognitive behavioural therapy which has been developed over the past 40 years. The treatment focusses on tracking and modifying eating behaviours, providing psychoeducation, addressing overvaluation of weight and shape, body image, food restriction and restraint, emotion regulation, and relapse prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy-Ten
Description: CBT-T is a 10-session treatment based on cognitive behavioural therapy. It was developed based on clinical experience as well as core components of evidence-based versions of CBT for eating disorders, including CBT-E. The aim of the intervention is to provide only the hypothesized critical elements of CBT for eating disorders so that the interventions can be provided quicker.
Study: NCT06129643

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional group
Description: conventional disinfection using 2.5% sodium hypochlorite and 17% EDTA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual laser group
Description: Er,Cr:YSGG intracanal laser irradiation to remove smear layer followed by diode laser for disinfection

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combined group
Description: 17% EDTA was used to remove smear layer followed by diode laser for disinfection
Study: NCT06216067

Intervention type: DEVICE
Intervention: CALLISTO eye
Description: Cataract toric lens placement tool

Intervention type: DEVICE
Intervention: Wavetec AnalyzOR
Description: Cataract toric lens placement tool
Study: NCT04457765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine (PVP-I)
Description: 1.25% Povidone-Iodine (PVP-I) (also known as betadine) to be used pre-procedure in the operating room via irrigation into the nasal cavity to act as viricidal preparation for the procedure. 240mL of 1.25% PVP-I will be distributed evenly among the right and left nasal cavities using a a 70mL syringe.
Study: NCT01235013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: 150 mg of Maraviroc every 12 hours (300 mg daily) orally for 24 weeks
Study: NCT05336786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren Lipid Microspheres
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Undergo ultrasound
Study: NCT06636019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myopia control contact lens
Description: Myopia control contact lens is placed on the study eye.
Study: NCT06571955

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of LARS artificial grafted ligament to treat ACL injury
Description: Implantation procedure will be realized by a well-trained orthopaedic surgeon and will consist of ACL repair using LARS artificial grafted ligament.
Study: NCT05900479

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PTSD Service Dog
Description: According to the Americans with Disabilities Act (ADA), a service dog is a dog that is trained to perform specific tasks to mitigate a disability. For PTSD service dogs, examples include detecting and alerting to physical signs of distress to interrupt anxiety and panic attacks, waking up Veterans from nightmares, and retrieving medication. In addition to trained tasks, service dogs live with the Veterans to provide emotional value as a source of comfort and companionship. Under the ADA guidance, PTSD service dogs have pubic access and are legally allowed to accompany their person in public places such as grocery stores, workplaces, and schools. In the proposed study, service dogs will be sourced from two Assistance Dog International (ADI) accredited providers, including K9s For Warriors and Canine Companions for Independence. Both providers have an established track record of training and providing PTSD service dogs, as well as collaborating with the investigative team in research.
Study: NCT05026463

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inspiratory support level
Description: Inspiratory support is the pressure delivered by the ventilator during pressure support ventilation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inspiratory support level
Description: Inspiratory support is the pressure delivered by the ventilator during pressure support ventilation.
Study: NCT06571955

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of LARS artificial non-grafted ligament to treat ACL injury
Description: Implantation procedure will be realized by a well-trained orthopaedic surgeon and will consist of ACL repair using LARS artificial non-grafted ligaments.
Study: NCT06647043

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SMT04 Pro
Description: Consists of a blend of food-grade Bifidobacterium as active probiotics
Study: NCT05026463

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inspiratory support level
Description: Inspiratory support is the pressure delivered by the ventilator during pressure support ventilation.
Study: NCT04677946

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Linoleic Acid Healthy Cookies
Description: High Linoleic Acid Healthy Cookies (containing about 9g of linoleic acid) 1 per day for 8 weeks
Study: NCT05439603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANC-501
Description: Five 10 mg capsules per day
Study: NCT05937048

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albumin
Description: 20% human albumin solution infusion, to raise and maintain serum albumin levels above 3.0 g/dl. Human albumin solution will be given to those enrolled in the study having serum albumin levels ≤ 3 g/dl to maintain the serum albumin levels above 3 g/dl.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard treatment that the patient would receive had they not been included in the trial.
Study: NCT04387227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study: NCT05940935

Intervention type: PROCEDURE
Intervention: Arterial Blood Gas Base Deficit
Description: The base deficit values in the preoperative, intraoperative and postoperative blood gases taken from the patients and the presence and severity of metabolic acidosis were evaluated. Metabolic acidosis severity was defined by base deficit levels: mild from -3 to -5, moderate from -5 to -10, and severe metabolic acidosis below -10.

Intervention type: PROCEDURE
Intervention: Arterial Blood Gas Base Deficit
Description: The base deficit values in the preoperative, intraoperative and postoperative blood gases taken from the patients and the presence and severity of metabolic acidosis were evaluated. Metabolic acidosis severity was defined by base deficit levels: mild from -3 to -5, moderate from -5 to -10, and severe metabolic acidosis below -10.

Intervention type: PROCEDURE
Intervention: Arterial Blood Gas Base Deficit
Description: The base deficit values in the preoperative, intraoperative and postoperative blood gases taken from the patients and the presence and severity of metabolic acidosis were evaluated. Metabolic acidosis severity was defined by base deficit levels: mild from -3 to -5, moderate from -5 to -10, and severe metabolic acidosis below -10.

Intervention type: PROCEDURE
Intervention: Arterial Blood Gas Base Deficit
Description: The base deficit values in the preoperative, intraoperative and postoperative blood gases taken from the patients and the presence and severity of metabolic acidosis were evaluated. Metabolic acidosis severity was defined by base deficit levels: mild from -3 to -5, moderate from -5 to -10, and severe metabolic acidosis below -10.
Study: NCT04683991

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subepithelial connective tissue graft
Description: A de-epithelialized connective tissue graft is harvested from the homolateral palate and transplanted around the implant.
Study: NCT04387227

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT04387227

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT06336369

Intervention type: DIAGNOSTIC_TEST
Intervention: analyzing brown adipose tissue, body composition and metabolic health
Description: cooling procedure, PET-CT imaging, MR imaging, blood sampling, indirect calorimetry, thermograpy, impedance analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: analyzing brown adipose tissue, body composition and metabolic health
Description: cooling procedure, PET-CT imaging, MR imaging, blood sampling, indirect calorimetry, thermograpy, impedance analysis
Study: NCT05846152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Patient wounds will be examined:~* by eye by the principal investigator~* using a ruler by the principal investigator~* by WoundCare algorithms (AKA WoundTrack) using smartphone photography by the principal investigator~* by eye by a second investigator~* using a ruler by a second investigator~* by WoundCare (AKA WoundTrack) algorithms using smartphone photography by a second investigator.
Study: NCT04054323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Description: The physical activity intervention will include basic skill training during which the participant will be instructed on the use of (1) the activPAL physical activity device for the tracking of time spent sitting, standing, and walking, (2) tools to monitor exercise intensity, including ratings of perceived exertion, (3) an exercise calendar for setting a specific schedule for the completion of the home exercise program using the exercise videos posted on our website, (4) use of the exercise equipment that will be used in the home program (Therabands), and (5) strategies for reduction of sedentary behavior that target prolonged sitting and encourages frequent activity breaks. Duration of intervention is 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Description: The physical activity intervention will include basic skill training during which the participant will be instructed on the use of (1) the activPAL physical activity device for the tracking of time spent sitting, standing, and walking, (2) tools to monitor exercise intensity, including ratings of perceived exertion, (3) an exercise calendar for setting a specific schedule for the completion of the home exercise program using the exercise videos posted on our website, (4) use of the exercise equipment that will be used in the home program (Therabands), and (5) strategies for reduction of sedentary behavior that target prolonged sitting and encourages frequent activity breaks. Duration of intervention is 6 months.